Status:
COMPLETED
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
Lead Sponsor:
Seoul National University Hospital
Conditions:
Recurrent HCC
Ablation Techniques, RFA
Eligibility:
All Genders
20-85 years
Phase:
NA
Brief Summary
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating ...
Detailed Description
The primary endpoint was defined as the 2-year cumulative incidence of LTP of the ablation index tumor, measured from the RFA date to first LTP occurrence. Secondary endpoints encompassed technical su...
Eligibility Criteria
Inclusion
- Age: 20-85 years Child-Pugh Class A liver function Radiologically confirmed locally recurrent HCC following conventional TACE treatment Recurrent HCC defined as arterially enhancing tumor at the edge of treated tumor
Exclusion
- More than three HCC nodules Tumors with ≥5 mm abutment length to main hepatic veins or first branches of main portal vein HCC nodules ≥3 cm Platelet count ≤50,000/mm³ or INR prolongation ≥50% Extrahepatic metastasis or vascular invasion Child-Pugh class B or C ECOG performance status ≥3 Poor acoustic window or inability to achieve percutaneous access
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07192172
Start Date
September 1 2017
End Date
December 1 2020
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hosptial
Seoul, Seoul, South Korea, 03080